Katherine A Hughes1, Scott P Webster, Brian R Walker. 1. Clinical Fellow University of Edinburgh, Endocrinology Unit, Centre for Cardiovascular Science, Queen's Medical Research Institute, 47 Little France Crescent, Edinburgh EH16 4TJ, UK.
Abstract
BACKGROUND: Glucocorticoids such as cortisol are important regulators of fuel metabolism during starvation and stress. Chronic glucocorticoid excess induces obesity with multiple features of the metabolic syndrome. OBJECTIVE: In this article, we review the importance of glucocorticoids in metabolic syndrome and the approaches that have been explored to reduce glucocorticoid action as the basis for novel therapy of Type 2 diabetes and obesity. METHOD: We focus on the enzyme 11-beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1), which amplifies glucocorticoid concentrations in key metabolic tissues including liver and adipose tissue. RESULTS/ CONCLUSION: Several 11beta-HSD1 inhibitors are in late preclinical or early clinical development and we review here the properties of the class leaders and their potential as the next generation of drugs with multiple benefits in metabolic syndrome.
BACKGROUND: Glucocorticoids such as cortisol are important regulators of fuel metabolism during starvation and stress. Chronic glucocorticoid excess induces obesity with multiple features of the metabolic syndrome. OBJECTIVE: In this article, we review the importance of glucocorticoids in metabolic syndrome and the approaches that have been explored to reduce glucocorticoid action as the basis for novel therapy of Type 2 diabetes and obesity. METHOD: We focus on the enzyme 11-beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1), which amplifies glucocorticoid concentrations in key metabolic tissues including liver and adipose tissue. RESULTS/ CONCLUSION: Several 11beta-HSD1 inhibitors are in late preclinical or early clinical development and we review here the properties of the class leaders and their potential as the next generation of drugs with multiple benefits in metabolic syndrome.
Authors: Mansor Fazliana; Harvest F Gu; Claes-Göran Östenson; Mashitah Mohd Yusoff; W M Wan Nazaimoon Journal: J Nat Med Date: 2011-08-11 Impact factor: 2.343
Authors: Arne Meyer; Anna Vuorinen; Agnieszka E Zielinska; Petra Strajhar; Gareth G Lavery; Daniela Schuster; Alex Odermatt Journal: Drug Metab Dispos Date: 2013-06-26 Impact factor: 3.922
Authors: Roland H Stimson; Jonas Andersson; Ruth Andrew; Doris N Redhead; Fredrik Karpe; Peter C Hayes; Tommy Olsson; Brian R Walker Journal: Diabetes Date: 2008-10-13 Impact factor: 9.461
Authors: Carlos A Penno; Stuart A Morgan; Anna Vuorinen; Daniela Schuster; Gareth G Lavery; Alex Odermatt Journal: J Lipid Res Date: 2013-08-09 Impact factor: 5.922
Authors: R N Carter; J M Paterson; U Tworowska; D J Stenvers; J J Mullins; J R Seckl; M C Holmes Journal: J Neuroendocrinol Date: 2009-07-07 Impact factor: 3.627
Authors: K Kaur; R Hardy; M M Ahasan; M Eijken; J P van Leeuwen; A Filer; A M Thomas; K Raza; C D Buckley; P M Stewart; E H Rabbitt; M Hewison; M S Cooper Journal: Ann Rheum Dis Date: 2009-06-22 Impact factor: 19.103